{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:38:53Z","timestamp":1791639533206,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/mt.2016.43","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T07:21:00Z","timestamp":1456471260000},"page":"671-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus"],"prefix":"10.1016","volume":"24","author":[{"given":"Abdullah","family":"Ely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buhle","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Arbuthnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.43_bib1","series-title":"Hepatitis B: The Hunt for a Killer Virus","author":"Blumberg","year":"2002"},{"key":"10.1038\/mt.2016.43_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","article-title":"A \u201cNEW\u201d antigen in leukemia sera","volume":"191","author":"Blumberg","year":"1965","journal-title":"JAMA"},{"key":"10.1038\/mt.2016.43_bib3","unstructured":"WHO 2013 Hepatitis B Virus Fact Sheet No. 204 (Updated July 2013)"},{"key":"10.1038\/mt.2016.43_bib4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat Genet"},{"key":"10.1038\/mt.2016.43_bib5","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"10.1038\/mt.2016.43_bib6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0140-6736(84)91694-5","article-title":"Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection","volume":"1","author":"Botha","year":"1984","journal-title":"Lancet"},{"key":"10.1038\/mt.2016.43_bib7","first-page":"285","article-title":"Vertical transmission of hepatitis B and neonatal hepatitis B","author":"Stevens","year":"1980","journal-title":"Virus and the liver"},{"key":"10.1038\/mt.2016.43_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1038\/mt.2016.43_bib9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hep.26125","article-title":"A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant","volume":"57","author":"Sureau","year":"2013","journal-title":"Hepatology"},{"key":"10.1038\/mt.2016.43_bib10","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1038\/mt.2016.43_bib11","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1038\/mt.2016.43_bib12","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1038\/mt.2016.43_bib13","doi-asserted-by":"crossref","first-page":"e1004343","DOI":"10.1371\/journal.ppat.1004343","article-title":"The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1","volume":"10","author":"Ducroux","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1038\/mt.2016.43_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"key":"10.1038\/mt.2016.43_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1038\/mt.2016.43_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3748\/wjg.v20.i2.401","article-title":"Then and now: The progress in hepatitis B treatment over the past 20 years","volume":"20","author":"Halegoua-De Marzio","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1038\/mt.2016.43_bib17","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/JVI.75.6.2900-2911.2001","article-title":"Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice","volume":"75","author":"Raney","year":"2001","journal-title":"J Virol"},{"key":"10.1038\/mt.2016.43_bib18","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1038\/mt.2016.43_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","author":"Laras","year":"2006","journal-title":"Hepatology"},{"key":"10.1038\/mt.2016.43_bib20","article-title":"A T7 endonuclease I assay to detect TALEN-mediated targeted mutation of HBV cccDNA","author":"Bloom","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mt.2016.43_bib21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.43_bib22","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","article-title":"Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture","volume":"82","author":"Zimmerman","year":"2008","journal-title":"J Virol"},{"key":"10.1038\/mt.2016.43_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.43_bib24","doi-asserted-by":"crossref","first-page":"e97579","DOI":"10.1371\/journal.pone.0097579","article-title":"AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.43_bib25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1038\/mt.2016.43_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1087057112463066","article-title":"Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line","volume":"18","author":"Zhao","year":"2013","journal-title":"J Biomol Screen"},{"key":"10.1038\/mt.2016.43_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.43_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hum.2013.062","article-title":"Optimizing retroviral gene expression for effective therapies","volume":"24","author":"Antoniou","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.43_bib29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1038\/mt.2016.43_bib30","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1038\/mtna.2013.75","article-title":"In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease","volume":"3","author":"Aubert","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mt.2016.43_bib31","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mt.2016.43_bib32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/CRISPR-associated Cas9 system to disrupt the hepatitis B virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2016.43_bib33","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.3748\/wjg.v21.i32.9554","article-title":"Dual gRNAs guided CRISPR\/Cas9 system inhibits hepatitis B virus replication","volume":"21","author":"Wang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1038\/mt.2016.43_bib34","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting Hepatitis B Virus With CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mt.2016.43_bib35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"10.1038\/mt.2016.43_bib36","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis B virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1038\/mt.2016.43_bib37","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1128\/JVI.01024-14","article-title":"Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice","volume":"88","author":"Qi","year":"2014","journal-title":"J Virol"},{"key":"10.1038\/mt.2016.43_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1038\/mt.2016.43_bib39","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1038\/mt.2016.43_bib40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2016.43_bib41","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"10.1038\/mt.2016.43_bib42","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci Rep"},{"key":"10.1038\/mt.2016.43_bib43","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1038\/mt.2016.43_bib44","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1038\/mt.2016.43_bib45","doi-asserted-by":"crossref","first-page":"e1003131","DOI":"10.1371\/journal.pcbi.1003131","article-title":"Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach","volume":"9","author":"Schiffer","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1038\/mt.2016.43_bib46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2015.12.007","article-title":"Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy","volume":"126","author":"De Silva Feelixge","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1038\/mt.2016.43_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1038\/mt.2016.43_bib48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1038\/mt.2016.43_bib49","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1093\/nar\/gku305","article-title":"TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity","volume":"42","author":"Mussolino","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mt.2016.43_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nmeth.1680","article-title":"On target? Tracing zinc-finger-nuclease specificity","volume":"8","author":"Mussolino","year":"2011","journal-title":"Nat Methods"},{"key":"10.1038\/mt.2016.43_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161630990X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161630990X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:49:56Z","timestamp":1761500996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161630990X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S152500161630990X"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.43","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2016.43","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}